Plasminogen Activator Inhibitor-1 Is Involved in Streptozotocin-Induced Bone Loss in Female Mice

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIG. 2.
FIG. 2.

Effects of PAI-1 deficiency on diabetic bone loss in both sexes of mice. Hematoxylin-eosin staining of tibia in control and streptozotocin-treated male and female PAI-1 WT and KO mice (A). BMD values in total, trabecular, and cortical bones (B); cortical thickness (C); and second moment of minimum and polar areas (D) of tibia in control and streptozotocin-treated male PAI-1 WT and KO mice. BMD values in total, trabecular, and cortical bones (E); cortical thickness (F); and second moment of minimum and polar areas (G) of tibia in control and streptozotocin-treated female PAI-1 WT and KO mice. For assessment of trabecular BMD, trabecular regions of interest extended from 96 um distal to the end of the proximal growth plate over 1.5 mm toward the diaphysis. For assessment of cortical BMD and thickness, cortical ROIs were defined as 2.0-mm segments of the mid-diaphysis tibia. For assessment of total BMD and bone strength index (second moment of minimum and polar areas: index of bending strength), ROIs were defined as 9,600-μm segment (100 slices) from distal end of proximal growth plate of tibia. Parameters used for the CT scans were as follows: tube voltage, 50 kVp; tube current, 500 μA; integration time, 3.6 ms; axial field of view, 48 mm; and voxel size of 48 × 96 μm with a slice thickness of 96 μm. Bone parameters were analyzed using the LaTheta software (version 3.40). Results are expressed as means ± SEM. *P < 0.05, **P < 0.01 (n = 5–7 in each group). Cont, control; STZ, streptozotocin.

This Article

  1. Diabetes vol. 62 no. 9 3170-3179